시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 카테콜아민 시장 보고서(2025년)
Catecholamines Global Market Report 2025
상품코드 : 1764276
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,698,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,681,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,665,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

카테콜아민 시장 규모는 향후 몇 년 동안 강력한 성장세를 보일 것으로 예상되며, 2029년까지 5.9%의 연평균 성장률(CAGR)로 53억 6,000만 달러에 달할 것으로 예상됩니다. 예측 기간 동안 예상되는 성장은 중환자 치료 연구에 대한 투자 증가, 만성질환을 앓고 있는 노인의 증가, 신경전달물질 조절에 초점을 맞춘 의약품 연구 개발의 확대, 원격의료를 통한 응급 의료의 부상, 중환자 치료 의사결정에 인공지능의 통합 등에 기인합니다. 이 기간 동안 예상되는 주요 동향으로는 약물 제형의 혁신, 합성 및 장시간 작용하는 카테콜아민의 개발, 자동 주사기 및 프리필드 시린지 기술의 발전, 맞춤형 주사제에 3D 프린팅 활용, 서방형 카테콜아민 제제의 창출 등이 있습니다.

심혈관질환의 유병률 증가는 향후 몇 년 동안 카테콜아민 시장의 성장을 견인할 것으로 예상됩니다. 심혈관질환(CVD)은 관상동맥 질환, 심부전, 뇌졸중 등 심장과 혈관에 영향을 미치는 다양한 질환을 포함하며, CVD의 유병률 증가는 주로 운동 부족으로 인해 발생하는데, 앉아서 생활하는 습관은 비만, 고혈압, 심혈관계 질환과 같은 증상의 위험을 증가시키기 때문입니다. 카테콜아민은 아드레날린 수용체에 대한 작용을 통해 심박출량을 증가시키고, 혈관의 긴장을 조절하며, 혈압을 유지함으로써 심혈관질환 관리에 중요한 역할을 합니다. 이러한 작용은 중요한 장기로의 혈류를 개선하고, 심부전이나 쇼크와 같은 급성 상황에서 혈역학을 안정시키고, 약해진 심장 기능을 일시적으로 보완하는 데 도움이 됩니다. 예를 들어, 2023년 12월 호주 정부 기관인 호주 보건 복지 연구소는 의사가 인정한 관상동맥 심장 질환(CHD)으로 인한 사망자 수가 2021년 14,100명에서 2022년 14,900명으로 증가했다고 보고했습니다. 이처럼 심혈관질환의 유병률 증가가 카테콜아민 시장의 성장에 기여하고 있습니다.

카테콜아민 시장의 주요 기업들은 투약의 유연성을 높이고, 환자의 순응도를 높이며, 약물 낭비를 최소화하고, 중환자 치료 환경에서 투약을 간소화하기 위해 다중 용량 바이알과 같은 혁신적인 제형 개발을 우선시하고 있습니다. 멀티도즈 바이알은 여러 번 사용할 수 있는 약물을 보관하는 용기로, 오염의 위험 없이 반복적으로 사용할 수 있습니다. 포장 낭비를 줄이고, 치료 비용을 절감하며, 의료 전문가와 환자 모두에게 편리한 투약 옵션을 제공하는 데 기여합니다. 예를 들어, 독일에 본사를 둔 제약회사 프레제니우스 카비(Fresenius Kabi AG)는 2025년 5월 미국 헬스케어 시장에서 자사의 주사제 제품 포트폴리오의 전략적 확장을 상징하는 30mL당 30mg의 다중 용량 바이알 에피네프린 주사제 USP를 출시했습니다. 이 제제는 성인과 소아의 아나필락시스를 포함한 알레르기 반응의 응급 치료, 패혈증성 쇼크와 관련된 저혈압 성인 환자의 평균 동맥혈압 상승을 목적으로 합니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 코로나와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별·국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

제31장 기타 주요 기업과 혁신적 기업

제32장 세계의 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병

제34장 최근의 시장 동향

제35장 시장 잠재력이 높은 국가, 전략

제36장 부록

ksm
영문 목차

영문목차

Catecholamines are a group of closely related hormones produced by the adrenal glands, which are located above the kidneys. They play a key role in the body's stress or fear response and are central to the fight-or-flight mechanism. Catecholamine levels can be assessed through blood or urine tests and are commonly used in diagnosing conditions such as pheochromocytoma, paraganglioma, and certain neuroendocrine tumors.

The primary types of catecholamines include epinephrine, norepinephrine, and dopamine. Epinephrine functions as both a hormone and neurotransmitter, initiating the fight-or-flight response by quickly increasing heart rate, blood pressure, and airflow to essential organs. Catecholamines are used to treat various conditions, such as anaphylaxis, cardiac arrest, shock, acute asthma, hypertension, and others. They are available in multiple formulations, including syrups, injectables, tablets, and inhalants, and are distributed through hospital pharmacies, online pharmacies, and retail pharmacies. These therapies serve a wide range of end-users, including hospitals and clinics, pharmaceutical companies, research institutions, and emergency medical services.

The catecholamines market research report is one of a series of new reports from The Business Research Company that provides catecholamines market statistics, including catecholamines industry global market size, regional shares, competitors with a catecholamines market share, detailed catecholamines market segments, market trends and opportunities, and any further data you may need to thrive in the catecholamines industry. The catecholamines market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The catecholamines market size has grown strongly in recent years. It will grow from $4.01 billion in 2024 to $4.26 billion in 2025 at a compound annual growth rate (CAGR) of 6.3%. Growth during the historic period can be attributed to the rising incidence of cardiac arrest, an increase in Parkinson's disease cases, growing demand for emergency care medications, heightened awareness of acute care treatments, and an uptick in surgical procedures.

The catecholamines market size is expected to see strong growth in the next few years. It will grow to $5.36 billion in 2029 at a compound annual growth rate (CAGR) of 5.9%. The projected growth during the forecast period can be attributed to increased investments in critical care research, a growing elderly population with chronic illnesses, expanding pharmaceutical R&D focused on neurotransmitter modulation, the rise of telemedicine-guided emergency care, and the integration of artificial intelligence into critical care decision-making. Key trends expected during this period include innovations in drug formulation, the development of synthetic and longer-acting catecholamines, advancements in auto-injector and prefilled syringe technologies, the use of 3D printing for personalized injectables, and the creation of extended-release catecholamine formulations.

The rising incidence of cardiovascular diseases is expected to drive the growth of the catecholamines market in the coming years. Cardiovascular diseases (CVDs) encompass a range of disorders affecting the heart and blood vessels, including coronary artery disease, heart failure, and stroke. The growing prevalence of CVDs is largely due to physical inactivity, as a sedentary lifestyle increases the risk of conditions such as obesity, high blood pressure, and poor cardiovascular health. Catecholamines play a vital role in managing cardiovascular diseases by boosting cardiac output, regulating vascular tone, and maintaining blood pressure through their action on adrenergic receptors. These effects help improve blood flow to essential organs, stabilize hemodynamics in acute situations like heart failure or shock, and offer temporary compensation for weakened cardiac function. For example, in December 2023, the Australian Institute of Health and Welfare, a government agency in Australia, reported that doctor-certified deaths from coronary heart disease (CHD) rose from 14,100 in 2021 to 14,900 in 2022. Thus, the increasing incidence of cardiovascular diseases is contributing to the growth of the catecholamines market.

Leading companies in the catecholamines market are prioritizing the development of innovative formulations, such as multi-dose vials, to enhance dosing flexibility, boost patient compliance, minimize medication waste, and simplify administration in critical care environments. Multi-dose vials are containers that store multiple doses of a medication, enabling repeated use without risk of contamination. They contribute to reducing packaging waste, lowering treatment expenses, and offering convenient dosing options for both healthcare professionals and patients. For example, in May 2025, Fresenius Kabi AG, a pharmaceutical company based in Germany, introduced Epinephrine Injection, USP, in 30 mg per 30 mL multi-dose vials, representing a strategic expansion of its injectable product portfolio in the U.S. healthcare market. This formulation is intended for emergency treatment of allergic reactions, including anaphylaxis, in both adults and children, as well as for elevating mean arterial blood pressure in adult patients experiencing hypotension related to septic shock.

In July 2022, Silverback Therapeutics Inc., a biopharmaceutical company based in the US, merged with ARS Pharmaceuticals Inc. to advance the development and commercialization of neffy. Through this merger, ARS Pharmaceuticals and Silverback Therapeutics aim to accelerate the market introduction of neffy, a needle-free epinephrine nasal spray developed to overcome key limitations associated with traditional autoinjectors used for treating severe allergic reactions. ARS Pharmaceuticals Inc. is a US-based biopharmaceutical company that manufactures catecholamines.

Major players in the catecholamines market are Pfizer Inc., Fresenius Kabi USA LLC, Teva Pharmaceutical Industries Limited, Baxter International Inc., Amneal Pharmaceuticals Inc., Glenmark Pharmaceuticals Limited, Amphastar Pharmaceuticals Inc., ARS Pharmaceuticals Inc., Breckenridge Pharmaceutical Inc., Long Grove Pharmaceuticals LLC, Midas Pharma GmbH, Otto Chemie Private Limited, Central Drug House (P) Ltd., Kanto Chemical Co. Inc., Bowmed Ibisqus Limited, Lexicare Pharma Private Limited, Alice Pharma Private Limited, Junsei Chemical Co. Ltd., Adamis Pharmaceuticals Corporation, Nevakar Injectables Inc.

North America was the largest region in the catecholamines market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in catecholamines report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the catecholamines market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The catecholamines market consists of sales of dobutamine, isoproterenol, and levodopa. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Catecholamines Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on catecholamines market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for catecholamines ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The catecholamines market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Catecholamines Market Characteristics

3. Catecholamines Market Trends And Strategies

4. Catecholamines Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Catecholamines Growth Analysis And Strategic Analysis Framework

6. Catecholamines Market Segmentation

7. Catecholamines Market Regional And Country Analysis

8. Asia-Pacific Catecholamines Market

9. China Catecholamines Market

10. India Catecholamines Market

11. Japan Catecholamines Market

12. Australia Catecholamines Market

13. Indonesia Catecholamines Market

14. South Korea Catecholamines Market

15. Western Europe Catecholamines Market

16. UK Catecholamines Market

17. Germany Catecholamines Market

18. France Catecholamines Market

19. Italy Catecholamines Market

20. Spain Catecholamines Market

21. Eastern Europe Catecholamines Market

22. Russia Catecholamines Market

23. North America Catecholamines Market

24. USA Catecholamines Market

25. Canada Catecholamines Market

26. South America Catecholamines Market

27. Brazil Catecholamines Market

28. Middle East Catecholamines Market

29. Africa Catecholamines Market

30. Catecholamines Market Competitive Landscape And Company Profiles

31. Catecholamines Market Other Major And Innovative Companies

32. Global Catecholamines Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Catecholamines Market

34. Recent Developments In The Catecholamines Market

35. Catecholamines Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기